The Associations between Insomnia Severity and Health Outcomes in the United States
Journal of Clinical Medicine · 22.03.2023 · 12 (6) · 2438
DOI: 10.3390/jcm12062438 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 22.03.2023. Verfasst von François-Xavier Chalet und 7 weiteren Autor:innen. Beteiligte Einrichtung: Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123 Allschwil, Switzerland. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Idorsia Pharmaceuticals Ltd., Idorsia Pharmaceuticals US Inc..
Themen: Schlaf
Abstract (Originalsprache)
Little is known about the associations between insomnia severity, insomnia symptoms, and key health outcomes. Using 2020 United States National Health and Wellness Survey (NHWS) data, we conducted a retrospective, cross-sectional analysis to determine the associations between insomnia severity and a number of health outcomes germane to patients (health-related quality of life (HRQoL), employers and government (workplace productivity), and healthcare payers (healthcare resource utilization (HCRU)). The Insomnia Severity Index (ISI) questionnaire was used to evaluate overall insomnia severity. HRQoL was assessed using the physical and mental component summary scores of the Short Form-36v2 (SF-36v2) questionnaire, and health utility status was measured using the Short Form-6D (SF-6D) and EuroQoL-5D (EQ-5D) questionnaires. Workplace productivity was measured using the Work Productivity and Activity Impairment (WPAI) questionnaire. After adjusting for confounders, greater insomnia severity was significantly associated with worsened quality of life, decreased productivity, and increased HCRU in an apparent linear fashion. These findings have important implications for future research, including the need for specific assessment of insomnia symptoms and their impact on key health outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123 Allschwil, Switzerland.
- Idorsia Pharmaceuticals US Inc., One Radnor Corporate Center, Suite 101, 100 Matsonford Rd, Radnor, PA 19087, USA.
- Cerner Enviza, 51 Valley Stream Pkwy, Malvern, PA 19355, USA.
- Department of Psychology, Cervo Brain Research Centre, Laval University, Québec City, QC G1V 0A6, Canada.
- Sleep Disorders Center, Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
- Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Förderung
- Idorsia Pharmaceuticals Ltd.
- Idorsia Pharmaceuticals US Inc.
Zitieren
APA
Chalet, F. X., Saskin, P., Ahuja, A., Thompson, J., Olopoenia, A., Modi, K., Morin, C. M., & Wickwire, E. M. (2023). The Associations between Insomnia Severity and Health Outcomes in the United States. Journal of Clinical Medicine, 12(6), 2438. https://doi.org/10.3390/jcm12062438
Vancouver
Chalet FX, Saskin P, Ahuja A, Thompson J, Olopoenia A, Modi K, et al. The Associations between Insomnia Severity and Health Outcomes in the United States. Journal of Clinical Medicine. 2023;12(6):2438. doi:10.3390/jcm12062438
BibTeX
@article{Chalet2023,
author = {Chalet, François-Xavier and Saskin, Paul and Ahuja, Ajay and Thompson, Jeffrey and Olopoenia, Abisola and Modi, Kushal and Morin, Charles M and Wickwire, Emerson M},
title = {The Associations between Insomnia Severity and Health Outcomes in the United States},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {6},
pages = {2438},
doi = {10.3390/jcm12062438}
}
EUVIMED